Abstract FR577: Sex Specific Evidence Gaps in Contemporary Cardiovascular Guidelines: A Comparative Analysis of the 2024 ESC and 2025 AHA/ACC Recommendations
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.fr577 ↗Kurz gefasst
Leitlinie in der Zeitschrift Hypertension, 2026-10. Verfasst von Meghna Ajit und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Despite cardiovascular disease (CVD) being the leading cause of death in women, historical male predominance in clinical trials has led to persistent sex specific evidence gaps in cardiovascular guidelines. A direct comparison of sex specific recommendations across these two bodies has not been systematically performed. Methods & Results: We conducted a structured narrative and scoping review comparing sex specific recommendations across the 2024 ESC and 2025AHA/ACC guideline portfolios. Seven clinical domains were evaluated: (1) ACS/AMI symptom recognition, (2) non-obstructive coronary disease (ANOCA/INOCA/MINOCA/SCAD), (3) cardiovascular risk stratification, (4) hypertension in pregnancy and menopause, (5) procedural access equity, (6) antithrombotic safety, and (7) female specific risk factors (PCOS, endometriosis, adverse pregnancy outcomes). Each domain was independently assessed for the presence and strength of sex specific recommendations using a three tier classification: fully addressed, partially addressed with acknowledged gap, or not addressed. Authorship representation and sex disaggregated trial citation density were assessed as structural equity metrics. The 2025 AHA/ACC guidelines demonstrated stronger integration of sex specific language in ACS symptom recognition, revascularization equity, pregnancy related hypertension thresholds, and cardiovascular risk scoring via the sex and race calibrated PREVENT calculator. The 2024 ESC guidelines showed greater specificity in ANOCA/INOCA management. Both guideline bodies inadequately addressed menopause as a systematic cardiovascular risk modifier, with only 10 of 34 ESC guidelines acknowledging menopause in clinical recommendations. Female specific conditions including PCOS and endometriosis were absent from actionable recommendations in both portfolios. MINOCA and SCAD guidance in both bodies remains largely observational, lacking RCT derived antithrombotic, statin, or beta blocker recommendations. Sex disaggregated citations represented fewer than 2% of total references across ESC guidelines, and female authorship remained below 14% historically in the ESC vs. approximately 20% in the AHA.
Conclusions
Both the 2024 ESC and 2025 AHA/ACC guidelines have made progress in sex specific cardiovascular recommendations, yet substantial and clinically consequential gaps persist across both frameworks. Menopause, PCOS, MINOCA, SCAD, and antithrombotic pharmacology in women represent priority domains for future guideline development. Systematic inclusion of sex disaggregated trial data are essential to achieve equitable cardiovascular guideline evidence. These findings have direct implications for guideline writing committees, research funding priorities, and clinical practice in women's cardiovascular health.
Zitieren
APA
Ajit, M., & Choudhari, J. (2026). Abstract FR577: Sex Specific Evidence Gaps in Contemporary Cardiovascular Guidelines: A Comparative Analysis of the 2024 ESC and 2025 AHA/ACC Recommendations. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr577
Vancouver
Ajit M, Choudhari J. Abstract FR577: Sex Specific Evidence Gaps in Contemporary Cardiovascular Guidelines: A Comparative Analysis of the 2024 ESC and 2025 AHA/ACC Recommendations. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr577
BibTeX
@article{Ajit2026,
author = {Ajit, Meghna and Choudhari, Jinal},
title = {Abstract FR577: Sex Specific Evidence Gaps in Contemporary Cardiovascular Guidelines: A Comparative Analysis of the 2024 ESC and 2025 AHA/ACC Recommendations},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.fr577}
}
EUVIMED